AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35565744 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% trehalose solution
Number of subjects: 22
Study 35565744 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% trehalose solution
Number of subjects: 22
Study 35565744 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% trehalose solution
Number of subjects: 22
Study 35565744 — intervention group
Group type: COMPARATOR
Intervention: 8% glucose solution
Number of subjects: 22
Study 35565744 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 22
Study 34520431 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intravenous albumin infusions
Number of subjects: 0
Study 34520431 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 34289814 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 50
Study 34289814 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 50
Study 34289814 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral pain
Number of subjects: 50
Study 33482890 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-l-leucine (IB1001)
Number of subjects: 0
Study 32916658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 36078339 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL-group (multiplanar everyday movements)
Number of subjects: 19
Study 33539637 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 39
Study 33539637 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 39
Study 32686874 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg TCT daily
Number of subjects: 150
Study 32686874 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg TCT daily
Number of subjects: 150
Study 32686874 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 150
Study 36376222 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage (EBD)
Number of subjects: 54
Study 36376222 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous biliary drainage (PTBD)
Number of subjects: 54
Study 33440964 — intervention group
Group type: EXPERIMENTAL
Intervention: Local oxygen therapy (LOT)
Number of subjects: 0
Study 33440964 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35276840 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc dispersible tablet
Number of subjects: 174
Study 35276840 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powder (MNP)
Number of subjects: 174
Study 35276840 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 174
Study 34506874 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation (ETI) during manual chest compressions
Number of subjects: 303
Study 34506874 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube (LT) during manual chest compressions
Number of subjects: 303
Study 34506874 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation (ETI) during mechanical chest compressions
Number of subjects: 303
Study 34506874 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube (LT) during mechanical chest compressions
Number of subjects: 303
Study 34506874 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of ventilation per minute and duration of TI amplitude insufflation and exhalation
Number of subjects: 303
Study 35223726 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-refutational two-sided messages
Number of subjects: 1184
Study 35223726 — intervention group
Group type: EXPERIMENTAL
Intervention: Refutational two-sided messages
Number of subjects: 1184
Study 35223726 — intervention group
Group type: COMPARATOR
Intervention: One-sided messages
Number of subjects: 1184
Study 32227161 — intervention group
Group type: EXPERIMENTAL
Intervention: Used a placebo analgesic cream
Number of subjects: 180
Study 32227161 — intervention group
Group type: EXPERIMENTAL
Intervention: Merely possessed a placebo analgesic cream
Number of subjects: 180
Study 32227161 — intervention group
Group type: EXPERIMENTAL
Intervention: Possessed and used a placebo analgesic cream
Number of subjects: 180
Study 32227161 — intervention group
Group type: COMPARATOR
Intervention: Possessed a sham cream
Number of subjects: 180
Study 32227161 — intervention group
Group type: COMPARATOR
Intervention: No cream
Number of subjects: 180
Study 33705267 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet ID
Number of subjects: 68
Study 33705267 — intervention group
Group type: COMPARATOR
Intervention: ASA24
Number of subjects: 68
Study 32890015 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusion (50 mg kg-1 followed by 15 mg kg-1 h-1)
Number of subjects: 70
Study 32890015 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% saline infusion)
Number of subjects: 70
Study 33677113 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate spa therapy (18 days)
Number of subjects: 220
Study 33677113 — intervention group
Group type: COMPARATOR
Intervention: Delayed spa therapy (after 6 months)
Number of subjects: 220
Study 32565215 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34871745 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship intervention (ASI)
Number of subjects: 149
Study 34871745 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 149
Study 32331062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline (4, 6, and 8 mg/d)
Number of subjects: 317
Study 32331062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 35137935 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (300 mg capsule)
Number of subjects: 52
Study 35137935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 32020523 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day zinc supplement
Number of subjects: 56
Study 32020523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 36018353 — intervention group
Group type: EXPERIMENTAL
Intervention: Native tissue surgery
Number of subjects: 1348
Study 36018353 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological xenograft surgery
Number of subjects: 1348
Study 36018353 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh surgery
Number of subjects: 1348
Study 34074830 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit (2/d)
Number of subjects: 79
Study 34074830 — intervention group
Group type: EXPERIMENTAL
Intervention: Prunes (100 g/d)
Number of subjects: 79
Study 34074830 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (12 g/d)
Number of subjects: 79
Study 33100020 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin medications
Number of subjects: 263
Study 33100020 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin medications
Number of subjects: 263
Study 34075612 — intervention group
Group type: EXPERIMENTAL
Intervention: P218 (up to 1000 mg)
Number of subjects: 56
Study 33481808 — intervention group
Group type: EXPERIMENTAL
Intervention: Kato-Katz slides stored at room temperature
Number of subjects: 488
Study 33481808 — intervention group
Group type: COMPARATOR
Intervention: Kato-Katz slides stored in a refrigerator
Number of subjects: 488
Study 33481808 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole stool samples stored at room temperature for one day
Number of subjects: 488
Study 33481808 — intervention group
Group type: COMPARATOR
Intervention: Whole stool samples stored in the refrigerator for one day
Number of subjects: 488
Study 33481808 — intervention group
Group type: EXPERIMENTAL
Intervention: Stirring whole stool samples
Number of subjects: 488
Study 34058250 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1A: 2 sizes larger than the IABF with a 4% taper
Number of subjects: 120
Study 34058250 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1B: 2 sizes larger than the IABF with a 6% taper
Number of subjects: 120
Study 34058250 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2A: 3 sizes larger than the IABF with a 4% taper
Number of subjects: 120
Study 34058250 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2B: 3 sizes larger than the IABF with a 6% taper
Number of subjects: 120
Study 32852611 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathy, Yoga and Dietary interventions
Number of subjects: 116
Study 32852611 — intervention group
Group type: COMPARATOR
Intervention: Psycho‐social counselling
Number of subjects: 116
Study 33416294 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management at 39 weeks of gestation
Number of subjects: 2502
Study 33416294 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management at 40 weeks of gestation
Number of subjects: 2502
Study 33416294 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management at 41-42 weeks of gestation
Number of subjects: 2502
Study 33052454 — intervention group
Group type: COMPARATOR
Intervention: Urine NGAL levels in ALL survivors
Number of subjects: 86
Study 33052454 — intervention group
Group type: COMPARATOR
Intervention: Urine NGAL/creatinine ratio in ALL survivors
Number of subjects: 86
Study 33052454 — intervention group
Group type: COMPARATOR
Intervention: Urine KIM-1/creatinine ratio in ALL survivors
Number of subjects: 86
Study 33052454 — intervention group
Group type: COMPARATOR
Intervention: Urine KIM-1 levels in ALL survivors after 5 years
Number of subjects: 86
Study 33052454 — intervention group
Group type: COMPARATOR
Intervention: Urine NGAL levels in ALL survivors after 5 years
Number of subjects: 86
Study 33052454 — intervention group
Group type: COMPARATOR
Intervention: eGFR in ALL survivors after 5 years
Number of subjects: 86
Study 36042095 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 164
Study 36042095 — intervention group
Group type: COMPARATOR
Intervention: Active Control Condition (ACC)
Number of subjects: 164
Study 34338870 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRI assessment of pelvic soft tissue measurements
Number of subjects: 0
Study 34338870 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon's intuitive assessment of surgical difficulty
Number of subjects: 0
Study 32442189 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 205
Study 32442189 — intervention group
Group type: COMPARATOR
Intervention: Copper intrauterine device (C-IUD)
Number of subjects: 205
Study 34941083 — intervention group
Group type: EXPERIMENTAL
Intervention: MNF scoring system (derived from clinical risk factors including female gender, age > 60 years, WBC ≤5000/mm3, WBC ≥35,000/mm3, creatinine ≥1.6 mg/dL, pulse rate >130/min)
Number of subjects: 1503
Study 34941083 — intervention group
Group type: EXPERIMENTAL
Intervention: MNF scoring system (validation cohort)
Number of subjects: 1503
Study 32705205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium (BS) after femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 90
Study 32705205 — intervention group
Group type: COMPARATOR
Intervention: Femtosecond laser-assisted cataract surgery (FLACS) + DEX/TOB
Number of subjects: 90
Study 32705205 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification treatment (CPCS) + DEX/TOB
Number of subjects: 90
Study 32705205 — intervention group
Group type: COMPARATOR
Intervention: FLACS + pranoprofen
Number of subjects: 90
Study 32705205 — intervention group
Group type: EXPERIMENTAL
Intervention: FLACS + BS
Number of subjects: 90
Study 32705205 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies with SRA01/04 cells treated with UV
Number of subjects: 90
Study 36226829 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-28 schedule of CoronaVac
Number of subjects: 2302
Study 36226829 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-14 schedule of CoronaVac
Number of subjects: 2302
Study 36226829 — intervention group
Group type: COMPARATOR
Intervention: Both schedules of CoronaVac
Number of subjects: 2302
Study 32451933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide 500 lipasemic units (LSUs) twice daily
Number of subjects: 1450
Study 32451933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide 250 LSU twice daily + indistinguishable placebo
Number of subjects: 1450
Study 32451933 — intervention group
Group type: COMPARATOR
Intervention: Indistinguishable placebo
Number of subjects: 1450
Study 32451933 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1450
Study 32627975 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin‐down‐plus‐larynx‐tightening maneuver during feeding
Number of subjects: 237
Study 32627975 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 237
Study 35075679 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (esomeprazole 20 mg 4 times daily and amoxicillin 1000 mg 3 times daily for 14 days)
Number of subjects: 700
Study 35075679 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, all twice daily for 14 days)
Number of subjects: 700
Study 34032663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg/kg)
Number of subjects: 68
Study 34032663 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (0.07 mg/kg to a maximum of 5 mg)
Number of subjects: 68
Study 34032663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 68
Study 34032663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex and Neostigmine
Number of subjects: 68
Study 33405300 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary education intervention
Number of subjects: 12
Study 33405300 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12
Study 33405300 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit smartwatch for measuring activity
Number of subjects: 12
Study 33724204 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app intervention
Number of subjects: 200
Study 33724204 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 200
Study 32144438 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo resembling psilocybin
Number of subjects: 33
Study 35442179 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP Plus Peer
Number of subjects: 292
Study 35442179 — intervention group
Group type: COMPARATOR
Intervention: HCP support
Number of subjects: 292
Study 33296786 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block with 30 ml of 0.2% ropivacaine
Number of subjects: 64
Study 33296786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 ml of 0.9% saline)
Number of subjects: 64
Study 35991210 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3127804 (20 mg/kg)
Number of subjects: 95
Study 35991210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 34463432 — intervention group
Group type: COMPARATOR
Intervention: Islatravir (MK-8591) single doses (5 mg to 400 mg)
Number of subjects: 32
Study 34463432 — intervention group
Group type: COMPARATOR
Intervention: Islatravir (MK-8591) multiple doses (10 mg, 30 mg, 100 mg)
Number of subjects: 32
Study 34463432 — intervention group
Group type: COMPARATOR
Intervention: Islatravir (MK-8591)
Number of subjects: 32
Study 34463432 — intervention group
Group type: COMPARATOR
Intervention: Islatravir (MK-8591) single doses (greater than or equal to 5 mg)
Number of subjects: 32
Study 33226482 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Span‐Epiphyseal Ring (CSER)
Number of subjects: 24
Study 33226482 — intervention group
Group type: COMPARATOR
Intervention: Half Span‐Epiphyseal Ring (HSER)
Number of subjects: 24
Study 33226482 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cage-height (HH)
Number of subjects: 24
Study 33226482 — intervention group
Group type: COMPARATOR
Intervention: Normal cage-height (NH)
Number of subjects: 24
Study 32379638 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise (12-week intervention)
Number of subjects: 17
Study 32379638 — intervention group
Group type: COMPARATOR
Intervention: Sham Qigong (12-week intervention)
Number of subjects: 17
Study 32379638 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 17
Study 32379638 — intervention group
Group type: COMPARATOR
Intervention: Sham Qigong
Number of subjects: 17
Study 36063194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystocele repair with mesh (vaginal or laparoscopic approach)
Number of subjects: 205
Study 33309977 — intervention group
Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 0
Study 33309977 — intervention group
Group type: COMPARATOR
Intervention: SoC
Number of subjects: 0
Study 32312713 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg SDG/day (Brevail)
Number of subjects: 180
Study 32312713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 32312713 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 180
Study 35461260 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site integrated care model with adherence counseling
Number of subjects: 500
Study 35461260 — intervention group
Group type: COMPARATOR
Intervention: Referral to off-site clinics assisted by a patient navigator
Number of subjects: 500
Study 33371741 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom resting hand splint
Number of subjects: 19
Study 33371741 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated resting hand splint
Number of subjects: 19
Study 34693932 — intervention group
Group type: EXPERIMENTAL
Intervention: De Simone Formulation Probiotic (DSFP; 'Visbiome') for 48 weeks
Number of subjects: 29
Study 34693932 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 29
Study 32448770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab intravenously
Number of subjects: 51
Study 35829773 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite gel (NaOCl)
Number of subjects: 62
Study 35829773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel (CHX)
Number of subjects: 62
Study 35829773 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 62
Study 34934026 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Aid (CA)
Number of subjects: 72
Study 34934026 — intervention group
Group type: COMPARATOR
Intervention: No Digital Cognitive Aid
Number of subjects: 72
Study 33983371 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day regimen of Pyronaridine-artesunate (180:60 mg)
Number of subjects: 303
Study 33983371 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day regimen of Pyronaridine-artesunate (180:60 mg)
Number of subjects: 303
Study 33983371 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day regimen of Pyronaridine-artesunate (180:60 mg)
Number of subjects: 303
Study 33983371 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 303
Study 34229742 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin-piperine capsules (3 capsules/day; 1500 mg curcumin and 15 mg piperine daily) for 7 days
Number of subjects: 60
Study 34229742 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (3 capsules/day; 1515 mg maltodextrin daily) for 7 days
Number of subjects: 60
Study 34229742 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin-piperine capsules
Number of subjects: 60
Study 34229742 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study 36332652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination HIV prevention package including immediate ART initiation
Number of subjects: 3570
Study 36332652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination HIV prevention package excluding immediate ART initiation
Number of subjects: 3570
Study 36332652 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 3570
Study 32343994 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarette (nicotine concentration of 12 mg/ml)
Number of subjects: 40
Study 32343994 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 40
Study 35710251 — intervention group
Group type: EXPERIMENTAL
Intervention: adaptive, digital game‐based attention training programme
Number of subjects: 104
Study 35710251 — intervention group
Group type: COMPARATOR
Intervention: numeracy programme
Number of subjects: 104
Study 33076964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 120 mg methylprednisolone followed by methotrexate (increasing dose to 25 mg/week orally)
Number of subjects: 230
Study 33076964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (injection and tablets)
Number of subjects: 230
Study 33076964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 120 mg methylprednisolone followed by methotrexate
Number of subjects: 230
Study 36205701 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point injection of 2 U of botulinum toxin type A per side (simplified method)
Number of subjects: 55
Study 36205701 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized method with 2 to 5 U of botulinum toxin type A (total, 4 to 10 U) injected at one or two sites
Number of subjects: 55
Study 36205701 — intervention group
Group type: COMPARATOR
Intervention: Both methods (simplified and individualized)
Number of subjects: 55
Study 34481432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of cytoflavin daily for 10 days
Number of subjects: 45
Study 34481432 — intervention group
Group type: COMPARATOR
Intervention: Standard post-COVID rehabilitation protocol (pulse magnetic therapy, inhalation therapy, aeroion therapy, infrared laser therapy, course aerobic training, psychotherapy, and standard drug therapy)
Number of subjects: 45
Study 35382763 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA-3G
Number of subjects: 220
Study 35382763 — intervention group
Group type: COMPARATOR
Intervention: LMAS
Number of subjects: 220
Study 34133366 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing and virtual planning
Number of subjects: 40
Study 34133366 — intervention group
Group type: COMPARATOR
Intervention: Conventional free fibula flap
Number of subjects: 40